Gatifloxacin - AbbVie/Senju Pharmaceutical
Alternative Names: AM 1155; BMS 206584; Bonoq; Bonoq Uro; CG 5501; Gatiflo; Gesetz; Tequin; Zymar; ZymaxidLatest Information Update: 05 Nov 2023
At a glance
- Originator Kyorin Pharmaceutical
- Developer AbbVie; Allergan; Kyorin Pharmaceutical; Senju Pharmaceutical
- Class Antibacterials; Fluoroquinolones; Small molecules
- Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Infectious conjunctivitis
- Market Withdrawal Acute exacerbations of chronic bronchitis; Bacterial infections; Chlamydial infections; Gonorrhoea; Pneumonia; Respiratory tract infections; Sinusitis; Skin and soft tissue infections; Urinary tract infections
- Discontinued Anthrax; Otitis media